MAPT and Alzheimer disease: Given the overlapping clinical features with Alzheimer’s disease (AD) [15, 16], the analysis of the core AD-CSF biomarkers (i.e., amyloid-beta 1–40 and 1–42, Aβ1–40 and Aβ1–42 or the Aβ1–42/Aβ1–40 ratio; phosphorylated Tau181, pTau181; and total Tau, tTau) is often used to exclude AD diagnosis [17].